Prevalence of primary anti-tuberculosis drug resistance at the tertiary center in Saudi Arabia and associated risk factors

References

1. 1.↵
   World Health Organization. Global tuberculosis report 2019. World Health Organization; 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf
2. 2.↵
   1. Glasauer S,
   2. Altmann D,
   3. Hauer B,
   4. Brodhun B,
   5. Haas W,
   6. Perumal N.

   First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. PLoS One 2019; 14: e0217597.

   OpenUrl
3. 3.↵
   1. Aljadani R,
   2. Ahmed AE,
   3. Al-Jahdali H.

   Tuberculosis mortality and associated factors at King Abdulaziz Medical City Hospital. BMC Infect Dis 2019; 19: 427.

   OpenUrl
4. 4.↵
   1. Abouzeid MS,
   2. Al Hakeem RF,
   3. Memish ZA.

   Mortality among tuberculosis patients in Saudi Arabia (2001-2010). Ann Saudi Med 2013; 33: 247–252.

   OpenUrl
5. 5.↵
   1. Al-Orainey I,
   2. Alhedaithy MA,
   3. Alanazi AR,
   4. Barry MA,
   5. Almajid FM.

   Tuberculosis incidence trends in Saudi Arabia over 20 years: 1991-2010. Ann Thorac Med 2013; 8: 148–152.

   OpenUrlCrossRef
6. 6.↵
   1. Stosic M,
   2. Vukovic D,
   3. Babic D,
   4. Antonijevic G,
   5. Foley KL,
   6. Vujcic I, et al.

   Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: A case-control study. BMC Public Health 2018; 18: 1114.

   OpenUrl
7. 7.↵
   1. Dheda K,
   2. Gumbo T,
   3. Maartens G,
   4. Dooley KE,
   5. McNerney R,
   6. Murray M, et al.

   The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017: S2213-2600(17)30079-6.
8. 8.↵
   1. Vasava MS,
   2. Bhoi MN,
   3. Rathwa SK,
   4. Borad MA,
   5. Nair SG,
   6. Patel HD.

   Drug development against tuberculosis: Past, present and future. Indian J Tuberc 2017; 64: 252–275.

   OpenUrl
9. 9.↵
   1. Caminero JA,
   2. García-Basteiro AL,
   3. Rendon A,
   4. Piubello A,
   5. Pontali E,
   6. Migliori GB.

   The future of drug-resistant tuberculosis treatment: Learning from the past and the 2019 World Health Organization consolidated guidelines. Eur Respir J 2019; 54: 1901272.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Marks SM,
    2. Hirsch-Moverman Y,
    3. Salcedo K,
    4. Graviss EA,
    5. Oh P,
    6. Seaworth B, et al.

    Characteristics and costs of multidrug-resistant tuberculosis inpatient care in the United States, 2005-2007. Int J Tuberc Lung Dis 2016; 20: 435–441.

    OpenUrl
11. 11.
    1. Zhang P,
    2. Xu G,
    3. Song Y,
    4. Tan J,
    5. Chen T,
    6. Deng G.

    Challenges faced by multidrug-resistant tuberculosis patients in three financially affluent Chinese cities. Risk Manag Healthc Policy 2020; 13: 2387–2394.

    OpenUrl
12. 12.↵
    1. Fiebig L,
    2. Kollan C,
    3. Hauer B,
    4. Gunsenheimer-Bartmeyer B

    , an der Heiden M, Hamouda O, et al. HIV-Prevalence in Tuberculosis Patients in Germany, 2002-2009: An Estimation Based on HIV and Tuberculosis Surveillance Data. PLoS One 2012; 7: e49111.

    OpenUrlPubMed
13. 13.↵
    1. Sereti I,
    2. Bisson GP,
    3. Meintjes G

    1. Naidoo K,
    2. Naicker N.

    Epidemiology of drug-susceptible, drug-resistant tuberculosis and HIV in Africa. In: Sereti I, Bisson GP, Meintjes G, editors. HIV and Tuberculosis. Switzerland (AG): Springer Nature; 2020.
14. 14.↵
    1. Al Ammari M,
    2. Al Turaiki A,
    3. Al Essa M,
    4. Kashkary AM,
    5. Eltigani SA,
    6. Ahmed AE

    . Drug resistant tuberculosis in Saudi Arabia: An analysis of surveillance data 2014-2015. Antimicrob Resist Infect Control 2018; 7: 12.
15. 15.↵
    1. Kane JC,
    2. Elafros MA,
    3. Murray SM,
    4. Mitchell EMH,
    5. Augustinavicius JL,
    6. Causevic S, et al.

    Focus on drug-resistant tuberculosis. Antimicrob Resist Infect Control 2018; 7: 12.

    OpenUrl
16. 16.
    1. Pettit AC,
    2. Cummins J,
    3. Kaltenbach LA,
    4. Sterling TR,
    5. Warkentin J V.

    Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis. Int J Tuberc Lung Dis 2013; 17: 486–492.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Abdella K,
    2. Abdissa K,
    3. Kebede W,
    4. Abebe G.

    Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia. BMC Public Health 2015; 15: 599.

    OpenUrl
18. 18.↵
    European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2017. Sweden (SW): European Centre for Disease Prevention and Control.
19. 19.↵
    1. Van Der Werf MJ,
    2. Ködmön C,
    3. Hollo V,
    4. Sandgren A,
    5. Zucs P.

    Drug resistance among tuberculosis cases in the European Union and European economic area, 2007 to 2012. Eurosurveillance 2014; 19: pii=20733.
20. 20.↵
    1. Chaudhry LA,
    2. Rambhala N,
    3. Al-Shammri AS,
    4. Al-Tawfiq JA.

    Patterns of antituberculous drug resistance in Eastern Saudi Arabia: A 7-year surveillance study from 1/2003 to 6/2010. J Epidemiol Glob Health 2012; 2: 57–60.

    OpenUrl
21. 21.↵
    1. Al-Hajoj S,
    2. Varghese B,
    3. Shoukri MM,
    4. Al-Omari R,
    5. Al-Herbwai M,
    6. AlRabiah F, et al.

    Epidemiology of antituberculosis drug resistance in Saudi Arabia: Findings of the first national survey. Antimicrob Agents Chemother 2013; 57: 2161–2166.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Sambas MFMK,
    2. Rabbani U,
    3. Al-Gethamy MMM,
    4. Surbaya SH,
    5. Alharbi FFI,
    6. Ahmad RGA, et al.

    Prevalence and determinants of multidrug-resistant tuberculosis in Makkah, Saudi Arabia. Infect Drug Resist 2020; 13: 4031–4038.

    OpenUrl
23. 23.↵
    1. Lewinsohn DM,
    2. Leonard MK,
    3. Lobue PA,
    4. Cohn DL,
    5. Daley CL,
    6. Desmond E, et al.

    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64: 111–115.

    OpenUrlCrossRefPubMed
24. 24.↵
    KDIGO. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Nephrol Dial 2017; 7: 1–59.

    OpenUrl
25. 25.↵
    1. Kwo PY,
    2. Cohen SM,
    3. Lim JK.

    ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017; 112: 18–35.

    OpenUrlCrossRef
26. 26.↵
    1. Al Mazroa MA,
    2. Kabbash IA,
    3. Felemban SM,
    4. Stephens GM,
    5. Al-Hakeem RF,
    6. Zumla AI, et al.

    HIV Case Notification Rates in the Kingdom of Saudi Arabia over the Past Decade (2000-2009). PLoS One 2012; 7: e45919.

    OpenUrlPubMed
27. 27.↵
    1. Shamaei M,
    2. Marjani M,
    3. Chitsaz E,
    4. Kazempour M,
    5. Esmaeili M,
    6. Farnia P, et al.

    First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran-eight years of surveillance. Int J Infect Dis 2009; 13: e236–e240.
28. 28.↵
    1. Gaifer Z,
    2. Babiker A,
    3. Rizavi D.

    Epidemiology of drug-resistant tuberculosis in a tertiary care center in Oman, 2006-2015. Oman Med J 2017; 32: 36–40.

    OpenUrl
29. 29.↵
    1. Al-Tawfiq JA,
    2. Al-Muraikhy AA,
    3. Abed MS.

    Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian Hospital: A 15-year study from 1989 to 2003. Chest 2005; 128: 3229–3232.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Falzon D,
    2. Linh Nhat N,
    3. Ernesto J,
    4. Karin W.

    The global response to rifampicin-resistant tuberculosis: Current situation and recent trends. European Respiratory Journal 2016; 48: PA1903.
31. 31.↵
    1. Tanoue LT.

    Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Yearbook of Pulmonary Disease 2007; 2007: 353–354.

    OpenUrl
32. 32.↵
    1. Xu Y,
    2. Wu J,
    3. Liao S,
    4. Sun Z.

    Treating tuberculosis with high doses of anti-TB drugs: Mechanisms and outcomes. Ann Clin Microbiol Antimicrob 2017; 16: 67.

    OpenUrl
33. 33.↵
    1. Wu X,
    2. Yang J,
    3. Tan G,
    4. Liu H,
    5. Liu Y,
    6. Guo Y, et al.

    Drug resistance characteristics of mycobacterium tuberculosis isolates from patients with tuberculosis to 12 antituberculous drugs in China. Front Cell Infect Microbiol 2019; 9: 345.

    OpenUrl
34. 34.↵
    1. Ullah I,
    2. Javaid A,
    3. Tahir Z,
    4. Ullah O,
    5. Shah AA,
    6. Hasan F, et al.

    Pattern of drug resistance and risk factors associated with development of drug resistant mycobacterium tuberculosis in Pakistan. PLoS One 2016; 11: e0147529.

    OpenUrl
35. 35.↵
    1. Wang MG,
    2. Huang WW,
    3. Wang Y,
    4. Zhang YX,
    5. Zhang MM,
    6. Wu SQ, et al.

    Association between tobacco smoking and drug-resistant tuberculosis. Infection and Drug Resistance 2018; 11: 873–887.

    OpenUrl
36. 36.↵
    1. Baya B,
    2. Achenbach CJ,
    3. Kone B,
    4. Toloba Y,
    5. Dabitao DK,
    6. Diarra B, et al.

    Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Int J Infect Dis 2019; 81: 149–155.

    OpenUrl
37. 37.↵
    1. Chingonzoh R,
    2. Manesen MR,
    3. Madlavu MJ,
    4. Sopiseka N,
    5. Nokwe M,
    6. Emwerem M, et al.

    Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013. PLoS One 2018; 13: e0202469.

    OpenUrl
38. 38.↵
    1. Cao Z,
    2. Lan Y,
    3. Chen L,
    4. Xiang M,
    5. Peng Z,
    6. Zhang J, et al.

    Resistance to first-line antituberculosis drugs and prevalence of pnca mutations in clinical isolates of mycobacterium tuberculosis from zunyi, guizhou province of China. Infect Drug Resist 2019; 12: 3093–3102.

    OpenUrl